par Joss, Rudolf;Hansen, Heine;Hansen, Mogens;Renard, Josette;Rozencweig, Marcel 
Référence European journal of cancer & clinical oncology, 20, 4, page (495-499)
Publication Publié, 1984
Référence European journal of cancer & clinical oncology, 20, 4, page (495-499)
Publication Publié, 1984
Article révisé par les pairs
| Résumé : | Epirubicin, a steroisomer of doxorubicin with suggested lower potential for cardiotoxicity in animal tumor systems, was evaluated in a disease-oriented phase II trial in non-small cell lung cancer. The drug was given as a direct i.v. injection of 90 mg/m2 repeated every 3 weeks. Four partial remissions were observed among 75 evaluable patients. Forty-two of the 75 patients had received no prior chemotherapy. The predicted true response rate is equal to 5% (0.2-10%). Leucopenia (75% of patients), gastrointestinal disturbances (76% of patients) and alopecia (53% of patients) were common side-effects observed. Four patients had cardiac abnormalities after treatment with epirubicin (one sinustachycardia, two premature beats, one biopsy-proven cardiomyopathy with congestive heart failure). One patient developed a peripheral neuropathy possibly related to epirubicin. We conclude that epirubicin in the present dose and schedule is an inactive agent in patients with non-small cell lung cancer. © 1984. |
